Device Trial Radar · NCT00351559
IMAGE: A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection
Last checked: Nov 20, 2026Latest source record: Nov 20, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
629
Actual
Start
Jan 2005
Primary completion
Not stated
Study completion Oct 2009
Sponsor
- Lead sponsor
- XDxNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 13, 2006
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the safety and efficacy of a leukocyte gene expression profiling method in the monitoring of asymptomatic heart transplant patients for acute rejection.
Conditions
- Graft Rejection
- Heart Diseases
Interventions
AlloMap molecular expression testingDevice
Right ventricular endomyocardial biopsyProcedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time from study enrollment to the earliest date of decrease in left ventricle function (left ventricular ejection fraction [LVEF] decrease ≥ 25% from baseline)
- Time from study enrollment to the development of clinically overt rejection (heart failure, hemodynamic compromise)
- Time from study enrollment to death from any cause
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
VA Palo Alto Health Care System
Palo Alto, California
Stanford University Medical Center
Stanford, California
Northwestern University
Chicago, Illinois
10 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.